SCOTUS ruling is a blow to small companies on the frontline of life sciences innovation

SCOTUS ruling is a blow to small companies on the frontline of life sciences innovation

The court’s decision in Helsinn Healthcare v Teva Pharmaceutical will disappoint the many biopharma businesses that depend on pre-marketing drug development collaboration

Unlock unlimited access to all IAM content